ArticleInternational journal of cardiology. Heart & vasculature2020
Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis.
Article in International journal of cardiology. Heart & vasculature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- New-onset Anti-melanoma Differentiation-associated Gene 5 Antibody Positive Clinically Amyopathic Dermatomyositis Following COVID-19.Internal medicine (Tokyo, Japan) · 2026Article
- Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies.Blood cancer journal · 2026Review
- Cholesterol Metabolism in Cancer Patients: Mechanisms, Treatment-Related Effects, and Cardio-Oncology Management.Oncology research · 2026Review
- Hematopoietic and T-lymphopoiesis-stimulating effects of a fluorinated pyrazolopiperidine β-cyclodextrin complex in cyclophosphamide-induced hematopoietic suppression.Frontiers in pharmacology · 2026Article
- Cyclic Thrombocytopenia Treated With Platelet Transfusion and Oral Preparation Containing Hyaluronic Acid (Oralvisc).Clinical case reports · 2025Article
- Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism.Frontiers in immunology · 2025Review
- Unveiling the Immunostimulatory Potential of Rhus Toxicodendron in Immunocompromised Balb/C Mice Induced with Cyclophosphamide.Diseases (Basel, Switzerland) · 2024Article
- Article
- The Clinical Significance of Salusins in Systemic Sclerosis-A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2023Article
- Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues.Frontiers in cardiovascular medicine · 2022Review
- Hydroxyurea ameliorates atherosclerosis in ApoETheranostics · 2022Article
- Cardiac computed tomography-derived extracellular volume fraction in the identification of cardiotoxicity: Another emerging imaging option.International journal of cardiology. Heart & vasculature · 2021Article
- Biological drug and drug delivery-mediated immunotherapy.Acta pharmaceutica Sinica. B · 2021Review
- Repurposing traditional immunomodulators to target the inflammatory burden of atherosclerosis.International journal of cardiology. Heart & vasculature · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerosis is a chronic inflammatory disease responsible for most cases of heart disease and stroke in Western countries. The cytotoxic drug cyclophosphamide (CPA) can modulate immune functions, and it has therefore been used to treat patients with autoimmune diseases. Extension of survival of patients with severe atherosclerosis has been reported after CPA treatment, but the underlying mechanism is still poorly understood. METHODS AND
resultsWe have investigated the effects of CPA in a murine model of atherosclerosis. Continuous oral administration of low-dose CPA (20 mg/kg/day) prevented atherosclerosis in apolipoprotein E-deficient (apoE
conclusionsThe results demonstrate that oral treatment with CPA inhibits initiation and progression of atherosclerosis in the apoE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.